Pharmaceuticals

Rise In Sports And Physical Activities Fueling The Growth Of The Due To Increasing Health Awareness Is Contributing To Changes In The Tumor Models Market

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Market Size Trajectory Of The Tumor Models Market From 2026 To 2030?

The tumor models market has experienced substantial expansion in its size over recent years. Forecasts indicate its value will ascend from $2.13 billion in 2025 to $2.37 billion by 2026, achieving a compound annual growth rate (CAGR) of 11.3%. The growth observed during the historic period stems from factors such as limited availability of advanced tumor models, reliance on traditional 2d cell cultures, growing cancer research funding, increasing prevalence of cancer, and the adoption of orthotopic and heterotopic models.

The tumor models market is poised for substantial growth over the next few years, with projections indicating it will reach $3.57 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 10.8%. This anticipated expansion can be attributed to advancements in organ-on-a-chip and 3D spheroid technologies, an increasing focus on personalized oncology treatments, the expansion of contract research organizations (CROs) in tumor research, rising pharmaceutical R&D expenditure, and the integration of AI and big data analytics in tumor model studies. Major trends during this period include the increasing use of 3D tumor spheroids and organ-on-a-chip models, a rising demand for personalized medicine and targeted cancer therapies, the expansion of xenograft and genetically engineered mouse models (GEMMs), growth in drug discovery and toxicology studies utilizing tumor models, and increased collaboration between pharmaceutical companies and academic institutions.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27441&type=smp

What Leading Drivers Are Supporting The Tumor Models Market Expansion?

The increasing need for personalized medical approaches is projected to fuel the expansion of the tumor models market in the future. This medical approach, known as personalized medicine, involves utilizing details about an individual’s genetic makeup and environmental factors to customize treatments and health services according to their unique requirements. The growing popularity of personalized medicine stems from individuals favoring health technologies that provide real-time monitoring and therapeutic strategies tailored to their distinct biological profiles. Tumor models assist personalized medicine by serving as experimental platforms that imitate the characteristics of actual human cancers, thereby enabling researchers and clinicians to assess and forecast how tumors from individual patients will react to particular therapies, leading to a more customized treatment strategy. As an example, in February 2024, data from the Personalized Medicine Coalition (PMC), a U.S. based nonprofit entity, indicated that the U.S. Food and Drug Administration (FDA) granted approval to 26 novel personalized medicines in 2023, marking a notable rise from the 12 approvals in 2022. Consequently, the escalating demand for personalized medicine is a key impetus for the expansion of the tumor models market.

How Is The Tumor Models Market Organized By Segment Classification?

The tumor models market covered in this report is segmented –

1) By Type Of Tumor: Primary Tumor Models, Metastatic Tumor Models, Orthotopic Tumor Models, Heterotopic Tumor Models

2) By Application: Drug Discovery And Development, Cancer Research, Personalized Medicine, Toxicology Studies

3) By Technology: Xenograft Models, Genetically Engineered Mouse Models (GEMMs), Three-Dimensional (3D) Tumor Spheroids, Organ-On-A-Chip Models

4) By End-User: Pharmaceutical And Biotechnology Companies, Academic Institutions, Contract Research Organizations (CROs), Government Research Organizations

Subsegments:

1) By Primary Tumor Models: Carcinoma Models, Sarcoma Models, Glioma Models, Melanoma Models, Leukemia Models, Lymphoma Models

2) By Metastatic Tumor Models: Lung Metastasis Models, Bone Metastasis Models, Liver Metastasis Models, Brain Metastasis Models, Lymph Node Metastasis Models

3) By Orthotopic Tumor Models: Orthotopic Breast Cancer Models, Orthotopic Lung Cancer Models, Orthotopic Pancreatic Cancer Models, Orthotopic Colon Cancer Models, Orthotopic Prostate Cancer Models

4) By Heterotopic Tumor Models: Subcutaneous Tumor Models, Intramuscular Tumor Models, Intraperitoneal Tumor Models

What Trends Are Affecting The Direction Of The Tumor Models Market?

Leading companies in the tumor models market are concentrating on developing advanced solutions, such as tumor spheroid models, to improve the physiological relevance and predictive accuracy of in vitro cancer models. Tumor spheroid models are characterized as three-dimensional (3D) aggregates of cancer cells that spontaneously form spherical structures in culture. For example, in June 2024, Predictive Oncology, a US-based provider of advanced 3D cell culture technologies and predictive oncology solutions, introduced novel 3D cell technology designed to accelerate cancer therapeutic drug discovery. This technology offers unique features, including advanced 3D tumor spheroid and organoid models that closely replicate the tumor microenvironment, high-throughput screening capabilities for rapid drug testing, support for patient-derived personalized tumor models, detailed analysis of drug penetration in 3D structures, and integration with AI-driven data analytics for enhanced predictive accuracy and deeper insights into therapeutic responses.

Who Are The Industry Participants Involved In The Tumor Models Market?

Major companies operating in the tumor models market are WuXi AppTec Co Ltd., Charles River Laboratories International Inc., Pharmaron Beijing Co. Ltd., The Jackson Laboratory, Taconic Biosciences Inc., Cyagen Biosciences Inc., Crown Bioscience Inc., Champions Oncology Inc., InSphero AG, Creative Biolabs Inc., Oncodesign S.A., Xentech S.A., MIMETAS BV, Experimental Pharmacology and Oncology Berlin-Buch GmbH.

Get The Full Tumor Models Market Report:

https://www.thebusinessresearchcompany.com/report/tumor-models-global-market-report

Which Region Accounts For The Largest Portion Of The Tumor Models Market?

North America was the largest region in the tumor models market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor models market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Tumor Models Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/tumor-models-global-market-report

Browse Through More Reports Similar to the Global Tumor Models Market 2026, By The Business Research Company

Voice Payment Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/voice-payment-software-global-market-report

Voice Banking Market Report 2026

https://www.thebusinessresearchcompany.com/report/voice-banking-global-market-report

Voice Commerce Market Report 2026

https://www.thebusinessresearchcompany.com/report/voice-commerce-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795